company background image
IONS logo

Ionis Pharmaceuticals NasdaqGS:IONS Stock Report

Last Price

US$34.11

Market Cap

US$5.4b

7D

5.0%

1Y

-33.6%

Updated

29 Jan, 2025

Data

Company Financials +

Ionis Pharmaceuticals, Inc.

NasdaqGS:IONS Stock Report

Market Cap: US$5.4b

IONS Stock Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. More details

IONS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Ionis Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ionis Pharmaceuticals
Historical stock prices
Current Share PriceUS$34.11
52 Week HighUS$52.49
52 Week LowUS$31.40
Beta0.36
1 Month Change-2.32%
3 Month Change-11.15%
1 Year Change-33.63%
3 Year Change8.29%
5 Year Change-42.17%
Change since IPO241.10%

Recent News & Updates

Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval

Dec 23

Investors Don't See Light At End Of Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Tunnel

Dec 23
Investors Don't See Light At End Of Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Tunnel

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Dec 01
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Recent updates

Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval

Dec 23

Investors Don't See Light At End Of Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Tunnel

Dec 23
Investors Don't See Light At End Of Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Tunnel

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Dec 01
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Aug 24
There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Aug 11

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Jul 28
Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

May 28

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09
Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Apr 14
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Mar 18
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Feb 23

Ionis Pharmaceuticals Looks Good For The Long Term

Oct 19

Ionis plans for new manufacturing site in California to support pipeline

Oct 13

Shareholder Returns

IONSUS BiotechsUS Market
7D5.0%2.1%-0.2%
1Y-33.6%-3.6%23.7%

Return vs Industry: IONS underperformed the US Biotechs industry which returned -3.6% over the past year.

Return vs Market: IONS underperformed the US Market which returned 23.7% over the past year.

Price Volatility

Is IONS's price volatile compared to industry and market?
IONS volatility
IONS Average Weekly Movement5.8%
Biotechs Industry Average Movement11.3%
Market Average Movement6.5%
10% most volatile stocks in US Market18.8%
10% least volatile stocks in US Market3.3%

Stable Share Price: IONS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: IONS's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1989927Brett Moniawww.ionis.com

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus.

Ionis Pharmaceuticals, Inc. Fundamentals Summary

How do Ionis Pharmaceuticals's earnings and revenue compare to its market cap?
IONS fundamental statistics
Market capUS$5.39b
Earnings (TTM)-US$358.81m
Revenue (TTM)US$803.07m

6.7x

P/S Ratio

-15.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IONS income statement (TTM)
RevenueUS$803.07m
Cost of RevenueUS$917.98m
Gross Profit-US$114.91m
Other ExpensesUS$243.90m
Earnings-US$358.81m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.27
Gross Margin-14.31%
Net Profit Margin-44.68%
Debt/Equity Ratio275.7%

How did IONS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/29 21:25
End of Day Share Price 2025/01/28 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ionis Pharmaceuticals, Inc. is covered by 47 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Huidong WangBarclays
James BirchenoughBarclays